Structure via PubChem · Public domain (PubChem)
bexarotene
Sign in to saveAlso known as LGD1069, Targrexin®, p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid, 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid, Bexaroten, 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, Bexaroteno, P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
Bexarotene, sold under the brand Targretin, is an antineoplastic (anti-cancer) agent used for the treatment of cutaneous T cell lymphoma (CTCL). It is a third-generation retinoid.
Chemical data
- Formula
- C24H28O2
- Molecular weight
- 348.5 g/mol
- IUPAC name
- 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
- SMILES
- CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
- InChIKey
- NAVMQTYZDKMPEU-UHFFFAOYSA-N
- XLogP
- 7.6
- Polar surface area
- 37.3 Ų
- H-bond donors
- 1
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1999
- Admin. routes
- oral, topical
- Indications
- non-small cell lung carcinoma, acute myeloid leukemia, alopecia areata, Cutaneous T-cell lymphoma
via ChEMBL · EBI
Research
1,019 papers- Bexarotene.American journal of clinical dermatology · 2000
- The novel function of bexarotene for neurological diseases.Ageing research reviews · 2023
- Bexarotene ligand pharmaceuticals.Current opinion in investigational drugs (London, England : 2000) · 2000
- Bexarotene: a clinical review.Expert review of anticancer therapy · 2004
- Bexarotene: a promising anticancer agent.Cancer chemotherapy and pharmacology · 2010
via PubMed
Wikidata facts
- Subclass of
- retinoid
- Mass
- 348.209
- Has use
- medication
Show 6 more facts
- Commons category
- Bexarotene
- chemical formula
- C₂₄H₂₈O₂
- canonical SMILES
- CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
- World Health Organisation international non-proprietary name
- bexarotene
- medical condition treated
- mycosis fungoides
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~4 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Interactions
- Mechanism
- Physical properties
- History
- References
- External links
Bexarotene, sold under the brand Targretin, is an antineoplastic (anti-cancer) agent used for the treatment of cutaneous T cell lymphoma (CTCL). It is a third-generation retinoid.
It was approved by the U.S. Food and Drug Administration (FDA) in December 1999, and the European Medicines Agency (EMA) in March 2001. It is available as a generic medication.
Excerpted from Wikipedia’s “bexarotene” article, available under the CC BY-SA 4.0 licence.